The new cancer drug developed by Novartis called Kisqali was approved by the FDA as a first-line treatment for metastatic breast cancer. The pill is intended as a combination treatment, designed for postmenopausal women who battle the condition.
The new cancer drug developed by Novartis called Kisqali was approved by the FDA as a first-line treatment for metastatic breast cancer. The pill is intended as a combination treatment, designed for postmenopausal women who battle the condition.
Share this Article
Recommended